| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | April 3, 2025 5:00 P.M. |
| Form: | S-3 | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
4 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Issuer)
4 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Issuer)
4 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Issuer)
All 27 patients completed treatment with no serious adverse events, underscoring a favorable safety profileStatistically significant improvements achieved across all efficacy endpoints at the 4-week timepointPreparing to initiate a pivotal Phase 2b study to advance LP-10 toward registration PITTSBURGH, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella," "we," "our," or the "Company"), a clinical-stage biotechnology company transforming care with innovative mucosal delivery solutions, today announced positive final results from its completed Phase 2a multicenter, dose-ranging study evaluating LP-10, a proprietary liposomal tacrolimus oral rinse, in pa
PITTSBURGH, Sept. 15, 2025 /PRNewswire/ -- Lipella Pharmaceuticals Inc. (OTC:LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company transforming care with innovative mucosal delivery solutions, today announced that Jonathan Kaufman, Chief Executive Officer of Lipella, will present a corporate overview and final results from Phase 2a trial of LP-10 in oral lichen planus at the Zacks SCR Life Sciences Virtual Investor Forum on September 18th, 2025 at 12:30pm EDT. Event Details: To register for the event and access the Lipella presentation webcast, click on th
PITTSBURGH, June 25, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (OTC:LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet need, today issued a letter from Chief Executive Officer Jonathan Kaufman to stockholders. The letter provides detailed responses to frequently asked questions regarding the Company's recent delisting from the Nasdaq Capital Market, as well as insight into Lipella's clinical programs, financial position, and plans to relist on a national exchange. In the letter, Dr. Kaufman acknowledged the many inquiries received from stockholders and reaffirmed the Company's commitmen
8-K - LIPELLA PHARMACEUTICALS INC. (0001347242) (Filer)
10-Q - LIPELLA PHARMACEUTICALS INC. (0001347242) (Filer)
8-K - LIPELLA PHARMACEUTICALS INC. (0001347242) (Filer)
4 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Issuer)
4 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Issuer)
SC 13G/A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Subject)
SC 13G/A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Subject)
SC 13D/A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Subject)